Introduction Hypertrophic cardiomyopathy (HCM) is a genetic, hereditary disease that can manifest in asymptomatic forms or severe conditions, including sudden death, with an estimated annual incidence of 0.5–1%., Symptomatic patients with left ventricular outflow tract (LVOT) obstruction may be candidates for septal reduction therapies. Surgical treatment is considered the gold standard, especially when there is an indication for valvular intervention in the same procedure. Percutaneous treatment has shown clinical results very similar to surgery, such as symptom improvement, gradient and […]